非典型抑郁具有独特的临床、神经生物学、治疗反应及多基因风险特征
在澳大利亚抑郁遗传学研究纳入的14897名参与者中,21%根据自报体重增加和嗜睡被归类为非典型抑郁。非典型抑郁与更早发病、更重病情、晚间偏好、较低日间光照、特定多基因风险评分升高及SSRI/SNRI疗效较差和副作用更多相关。
要点
- 非典型抑郁与更早发病、更重病情及晚间偏好相关。
- 非典型抑郁与代谢炎症相关多基因风险评分升高相关。
- 非典型抑郁与SSRI/SNRI自报疗效较差及体重增加副作用相关。
核心结论
- 非典型抑郁在临床和遗传风险特征上具有独特性,支持其作为指导治疗选择和躯体健康管理的亚型。
研究设计与样本
- 研究纳入澳大利亚抑郁遗传学研究14897名参与者,其中3098名(21%)根据自报体重增加和嗜睡被归类为非典型抑郁。
主要发现
- 非典型抑郁与更早发病年龄、更重疾病严重程度、更强晚间偏好及较少日间光照暴露相关。
- 非典型抑郁与重度抑郁、注意缺陷多动障碍、双相障碍、神经质、体重指数、2型糖尿病、C反应蛋白及胰岛素抵抗的多基因风险评分升高相关。
- 非典型抑郁与高密度脂蛋白胆固醇及时型(指示晚间偏好)的多基因风险评分降低相关。
- 非典型抑郁与选择性5-羟色胺再摄取抑制剂(SSRI)和5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)自报疗效较差及更多副作用相关。
关键数值与推荐
- 非典型抑郁与重度抑郁多基因风险评分的比值比(OR)为1.10(95% CI 1.06-1.15)。
- 非典型抑郁与体重指数多基因风险评分的OR为1.35(95% CI 1.29-1.42)。
- 非典型抑郁与SSRI自报疗效的OR为0.88(95% CI 0.81-0.96)。
- 非典型抑郁与SNRI自报疗效的OR为0.85(95% CI 0.77-0.94)。
- 非典型抑郁与体重增加副作用的OR为2.89(95% CI 2.66-3.15)。
临床怎么用
- 可考虑将非典型抑郁亚型用于指导抗抑郁药物选择,并关注体重增加等副作用。
- 对非典型抑郁患者应关注代谢炎症相关躯体健康管理。
局限性
- 非典型抑郁基于自报体重增加和嗜睡进行表型分类,非临床访谈确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atypical depression is considered a distinct clinical subtype of major depression, yet its predictive validity and clinical utility remain contested. We investigated associations between atypical depression and clinical characteristics, genetic profiles, and antidepressant responses. METHODS: Among 14,897 participants from the Australian Genetics of Depression Study (75% female; mean age 43.7 years), 3098 (21%) were classified phenotypically as having atypical depression based on self-reported weight gain and hypersomnia during their worst depressive episode. Demographic variables and clinical features were compared. Bonferroni-corrected regression models were used to evaluate associations between atypical depression and polygenic scores (PGSs) for mental disorders, metabolic-inflammatory-circadian traits, and self-reported antidepressant response and side effects. RESULTS: Atypical depression cases had an earlier age of onset, greater illness severity, stronger eveningness, and reduced daylight exposure. Atypical depression cases had higher PGSs for major depression (odds ratio [OR] = 1.10 [95% CI, 1.06-1.15]), attention-deficit/hyperactivity disorder (OR = 1.08 [1.04-1.13]), bipolar disorder (OR = 1.07 [1.02-1.12]), neuroticism (OR = 1.07 [1.02-1.12]), body mass index (OR = 1.35 [1.29-1.42]), type 2 diabetes (OR = 1.22 [1.16-1.28]), C-reactive protein (OR = 1.12 [1.07-1.17]), and insulin resistance (OR = 1.11 [1.06-1.16]) but lower PGSs for high-density lipoprotein cholesterol (OR = 0.91 [0.87-0.95]) and chronotype (indicating eveningness) (OR = 0.94 [0.90-0.98]). Atypical depression was associated with poorer self-reported effectiveness of selective serotonin reuptake inhibitors (OR = 0.88 [0.81-0.96]) and serotonin-norepinephrine reuptake inhibitors (OR = 0.85 [0.77-0.94]), as well as more side effects, particularly weight gain (OR = 2.89 [2.66-3.15]). CONCLUSIONS: This large, genetically informative study supports the neurobiological and clinical validity of atypical depression, demonstrating distinct clinical and genetic risk profiles alongside differential antidepressant responses. These findings support the use of the atypical subtype to guide treatment selection and physical health management.
引用
- Shin M, Crouse JJ, Lin T, et al. Atypical Depression Is Associated With a Distinct Clinical, Neurobiological, Treatment Response and Polygenic Risk Profile. Biol Psychiatry. 2026. PMID: 41534638. doi:10.1016/j.biopsych.2026.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。